Pharmacokinetics of 14C-labeled Isavuconazonium Sulfate
2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
BP
Basilea PharmaceuticaSwitzerland - Allschwil
1 program1
Pyridinylmethyl-14C-labeled isavuconazonium sulfatePhase 1
AstellasChina - Shenyang
1 program1
Pyridinylmethyl-14C-labeled isavuconazonium sulfatePhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AstellasPyridinylmethyl-14C-labeled isavuconazonium sulfate
Clinical Trials (1)
Total enrollment: 6 patients across 1 trials
A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects
Start: Apr 2013Est. completion: Apr 20136 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space